CTLA4 and neoplasm: In addition, the melanoma patients with combined anti-PD-1 and anti-CTLA-4 therapies revealed PD-1-expressing CD4+FOXP3- T cells (4PD-1hi), a unique suppressive T cell subset linked to higher tumor burden.